Responding to a rare rebuke from the F.D.A., Novartis's chief executive defended the company's decision to withhold information about manipulated data involving its $2.1 million gene therapy, Zolgensma. The company could face criminal or civil penalties.
Responding to a rare rebuke from the F.D.A., Novartis's chief executive defended the company's decision to withhold information about manipulated data involving its $2.1 million gene therapy, Zolgensma. The company could face criminal or civil penalties.
Responding to a rare rebuke from the F.D.A., Novartis's chief executive defended the company's decision to withhold information about manipulated data involving its $2.1 million gene therapy, Zolgensma. The company could face criminal or civil penalties.
TY for shout-out . Once again I find myself serving it up for . $NVS story still lacks clarity regarding why the was not informed during the review rather than post approval, and who at $NVS made the decision.
Absolutely abhorrent! This really disgusts me ⁦ via I don’t for a second buy the “few bad actors” BS - this is unacceptable in science and especially when patients and their families are involved.
This isn't going well. Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.